Selected article for: "SARS replication cycle and small molecule"

Author: Banerjee, Riddhidev; Perera, Lalith; Tillekeratne, L.M. Viranga
Title: Potential SARS-CoV-2 main protease inhibitors
  • Cord-id: nxqr58xv
  • Document date: 2020_12_9
  • ID: nxqr58xv
    Snippet: The coronavirus disease 2019 (COVID-19) pandemic has prompted an urgent need for new treatment strategies. No target-specific drugs are currently available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but new drug candidates targeting the viral replication cycle are being explored. A prime target of drug-discovery efforts is the SARS-CoV-2 main protease (M(pro)). The main proteases of different coronaviruses, including SARS-CoV-2, SARS-CoV and Middle East respiratory syndrom
    Document: The coronavirus disease 2019 (COVID-19) pandemic has prompted an urgent need for new treatment strategies. No target-specific drugs are currently available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but new drug candidates targeting the viral replication cycle are being explored. A prime target of drug-discovery efforts is the SARS-CoV-2 main protease (M(pro)). The main proteases of different coronaviruses, including SARS-CoV-2, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), share a structurally conserved substrate-binding region that can be exploited to design new protease inhibitors. With the recent reporting of the X-ray crystal structure of the SARS-CoV-2 M(pro), studies to discover M(pro) inhibitors using both virtual and in vitro screening are progressing rapidly. This review focusses on the recent developments in the search for small-molecule inhibitors targeting the SARS-CoV-2 M(pro).

    Search related documents:
    Co phrase search for related documents
    • acceptor base and active site near: 1, 2
    • acceptor base and active site residue: 1